特发性帕金森病血液基因表达分析
该研究基于523例外周血基因表达谱,经预处理后纳入486例(205例帕金森病、233例对照、48例其他神经退行性疾病),分为训练、验证和独立测试队列以识别并验证基因特征。研究识别出100个探针(对应87个基因)的基因特征,在验证队列(AUC=0.79,p=7.13E-6)和独立测试队列(AUC=0.74,p=4.2E-4)中成功重复,并富集于代谢、氧化、泛素化/蛋白酶体及线粒体相关基因失调通路。
要点
- 基于大样本外周血基因表达谱可识别稳健的帕金森病基因特征。
- 87基因特征在独立验证和测试队列中均显示可重复的区分能力。
- 该特征涉及代谢、氧化、泛素化/蛋白酶体及线粒体基因失调。
核心结论
- 大规模帕金森病基因表达谱研究识别出可靠的血液基因特征,并强调大样本队列对开发潜在生物标志物的重要性。
研究设计与样本
- 研究收集523例个体全血基因表达谱,预处理后获得486例基因谱(205例帕金森病、233例对照、48例其他神经退行性疾病),分为训练、验证和独立测试队列以识别和验证基因特征。
- 采用批次效应校正和交叉验证确保特征可靠性,并对特征进行功能和通路富集分析以识别帕金森病相关基因网络。
主要发现
- 训练队列识别出100个探针(对应87个基因)的基因特征,包括64个上调基因和23个下调基因,可区分特发性帕金森病患者与对照。
- 该特征在独立验证队列中成功重复(AUC=0.79,p=7.13E-6),并在后续独立测试队列中重复(AUC=0.74,p=4.2E-4)。
- 网络分析显示特征基因富集于代谢、氧化、泛素化/蛋白酶体活性等通路,以及线粒体定位基因失调,包括COX4I1、ATP5A1和VDAC3下调。
临床怎么用
- 该血液基因特征可作为帕金森病潜在生物标志物研究的候选,但尚未推荐用于临床诊断。
- 线粒体相关基因(COX4I1、ATP5A1、VDAC3)下调提示能量代谢通路可能参与帕金森病机制。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether gene expression analysis of a large-scale Parkinson disease (PD) patient cohort produces a robust blood-based PD gene signature compared to previous studies that have used relatively small cohorts (≤220 samples). METHODS: Whole-blood gene expression profiles were collected from a total of 523 individuals. After preprocessing, the data contained 486 gene profiles (n = 205 PD, n = 233 controls, n = 48 other neurodegenerative diseases) that were partitioned into training, validation, and independent test cohorts to identify and validate a gene signature. Batch-effect reduction and cross-validation were performed to ensure signature reliability. Finally, functional and pathway enrichment analyses were applied to the signature to identify PD-associated gene networks. RESULTS: A gene signature of 100 probes that mapped to 87 genes, corresponding to 64 upregulated and 23 downregulated genes differentiating between patients with idiopathic PD and controls, was identified with the training cohort and successfully replicated in both an independent validation cohort (area under the curve [AUC] = 0.79, p = 7.13E-6) and a subsequent independent test cohort (AUC = 0.74, p = 4.2E-4). Network analysis of the signature revealed gene enrichment in pathways, including metabolism, oxidation, and ubiquitination/proteasomal activity, and misregulation of mitochondria-localized genes, including downregulation of COX4I1, ATP5A1, and VDAC3. CONCLUSIONS: We present a large-scale study of PD gene expression profiling. This work identifies a reliable blood-based PD signature and highlights the importance of large-scale patient cohorts in developing potential PD biomarkers.
引用
- Shamir R, Klein C, Amar D, et al. Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology. 2017. PMID: 28916538. doi:10.1212/WNL.0000000000004516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。